Venetoclax, an approved medication for cancer, is effective at reducing simian immunodeficiency virus reservoir levels in vivo when given in combination with antiretroviral therapy. This study offers hope for accelerating the timeline to cure by using an approved medication.

Researchers at South China University of Technology developed a modular nano-adaptor platform that quantitatively tunes anti-CD3 presentation while preserving antibody affinity, total antibody loading and tumor-targeting capacity. The calibrated platform enabled screening of 91 tetraspecific nanoantibody configurations and identified lead combinations that strengthened immune–tumor interactions, improved antitumor activity and suppressed tumor growth in PBMC-humanized mouse models under the tested conditions.

People with inflammatory bowel disease (IBD) who have several close relatives with colorectal cancer are significantly more likely to develop the disease themselves. This is demonstrated by a new Swedish registry study from Karolinska Institutet, published in the journal Gastroenterology. The findings raise the question of whether future cancer screening guidelines should place greater emphasis on the number of cancer cases in a patient's family.

New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.

Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared with patients receiving intensive chemotherapy. Published in The New England Journal of Medicine, the findings could change the initial treatment approach for many patients with AML.